Biomarin Pharmaceutical (WBO:BMRN) EV-to-Revenue : 7.22 (As of Apr. 25, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Biomarin Pharmaceutical EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Biomarin Pharmaceutical's enterprise value is €16,191 Mil. Biomarin Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €2,244 Mil. Therefore, Biomarin Pharmaceutical's EV-to-Revenue for today is 7.22.

The historical rank and industry rank for Biomarin Pharmaceutical's EV-to-Revenue or its related term are showing as below:

WBO:BMRN' s EV-to-Revenue Range Over the Past 10 Years
Min: 6.54 Med: 11.19 Max: 27.8
Current: 7.16

During the past 13 years, the highest EV-to-Revenue of Biomarin Pharmaceutical was 27.80. The lowest was 6.54. And the median was 11.19.

WBO:BMRN's EV-to-Revenue is ranked better than
51.79% of 1033 companies
in the Biotechnology industry
Industry Median: 7.63 vs WBO:BMRN: 7.16

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-25), Biomarin Pharmaceutical's stock price is €86.12. Biomarin Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €11.68. Therefore, Biomarin Pharmaceutical's PS Ratio for today is 7.38.

Biomarin Pharmaceutical EV-to-Revenue Historical Data

The historical data trend for Biomarin Pharmaceutical's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical EV-to-Revenue Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

8.98

8.58

8.84

9.10

7.53

Biomarin Pharmaceutical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															9.10	8.37	7.26	7.20	7.53

Competitive Comparison of Biomarin Pharmaceutical's EV-to-Revenue

For the Biotechnology subindustry, Biomarin Pharmaceutical's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomarin Pharmaceutical's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's EV-to-Revenue falls into.

Biomarin Pharmaceutical EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Biomarin Pharmaceutical's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	16191.488	/	2243.768
	=	7.22

Biomarin Pharmaceutical's current Enterprise Value is €16,191 Mil.
Biomarin Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €2,244 Mil.

Biomarin Pharmaceutical (WBO:BMRN) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Biomarin Pharmaceutical's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	86.12	/	11.677
	=	7.38

Biomarin Pharmaceutical's share price for today is €86.12.
Biomarin Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.68.

Biomarin Pharmaceutical EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical (WBO:BMRN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (WBO:BMRN) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy BM8:Germany B1MR34:Brazil

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.